New combo therapy shows promise for tough lung cancer
NCT ID NCT06477523
First seen May 03, 2026 · Last updated May 15, 2026 · Updated 2 times
Summary
This study tests a new treatment for people with extensive-stage small cell lung cancer who haven't had treatment before. It combines a bispecific antibody (AK104) with chemotherapy and low-dose radiation to see if it's safe and helps control the cancer. About 57 adults aged 18 to 80 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
China West Hospital
Chengdu, Sichuan, 610000, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.